Drug Repurposing Approaches for Depression: Rationale and its Clinical Experience

Published: April 10, 2023


Mimansa Kandhwal, Amarjot Kaur Grewal, Varinder Singh, Heena Khan and Thakur Gurjeet Singh

Drug discovery, Repurposing, Artificial Intelligence, Depression, Mortality


Background: Drug discovery is a very time-consuming, tedious, and expensive process lasting for about two or more decades. This complexity of the process of drug discovery and the sluggish pace at which new drugs are being discovered draw the attention of scientists to redefine the whole process with the help of drug repurposing. The usage of old drug moieties in any other disorder with all new mechanisms is defined as repurposing. Repurposing of drugs knocks out the pre-clinical phase and related studies to give that molecule a redefined purpose. Data from these studies may be used in discovering newer molecules to save human effort, time, and expenses as well.

Purpose: The complex etiology of depression and resistance to its treatment drive novel discoveries via therapeutic repurposing and pharmacological repositioning to treat this complex disorder. In addition to the reduction of neurotransmitters such as epinephrine and serotonin, additional processes like inflammation, inadequate blood flow, and neurotoxicants are also being examined as possibly implicated mechanisms.

Methods: Data was extensively collected, thoroughly reviewed and analysed from research published in the respective field.

Results: Taking into consideration the aforementioned pathways has led to the development of repurposed drugs that can be used to treat treatment-resistant depression (TRD).
Conclusions: The incorporation of artificial intelligence in drug repurposing may also enhance the chances of its success rate as it deals with data digitalization which is the main core mechanism used in drug repurposing.


Abbruzzese, C., Matteoni, S., Persico, M., Villani, V.,&Paggi, M. G. (2020). Repurposing chlorpromazine in the treatment of glioblastoma multiforme: analysis of literature and forthcoming steps.

Journal of Experimental & Clinical Cancer Research, 39, 1-3.https://doi.org/10.1186/s13046-020-1534-z
Baker, N. C., Ekins, S., Williams, A. J.,& Tropsha, A. (2018). A bibliometric review of drug repurposing.Drug Discovery Today, 23(3), 661-672.https://doi.org/10.1016/j.drudis.2018.01.018

Balasegaram, M., Ritmeijer, K., Lima, M. A., Burza, S., Ortiz Genovese, G., Milani, B., … & Chappuis, F. (2012). Liposomal amphotericin B as a treatment for human leishmaniasis. Expert opinion on emerging drugs, 17(4), 493-510.https://doi.org/10.1517/14728214.2012.748036

Barden, N. (2004). Implication of the hypothalamic–pituitary–adrenal axis in the physiopathology of depression. Journal of Psychiatry and Neuroscience, 29(3), 185-193.

Bayramgürler, D., Karson, A., Özer, C., & Utkan, T. (2013). Effects of long-term etanercept treatment on anxiety-and depression-like neurobehaviors in rats. Physiology & Behavior, 119, 145-148.https://doi.org/10.1016/j.physbeh.2013.06.010

Brent, D., Emslie, G., Clarke, G., Wagner, K. D., Asarnow, J. R., Keller, M., … & Zelazny, J. (2008). Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. Jama, 299(8), 901-913.https://doi.org/10.1001/jama.299.8.901

Brunoni, A. R., Lopes, M. &F regni, F. (2008). A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. The International Journal of Neuropsychopharmacology, 11(8), 1169-1180.https://doi.org/10.1017/S1461145708009309

Bryan, J. (2011). How minoxidil was transformed from an antihypertensive to hair-loss drug. Pharmaceutical Journal, 287(7663), 137.https://doi.org/10.1211/PJ.2021.1.69888

Cain, R.A., (2007). Navigating the sequenced treatment alternatives to relieve depression (STAR∗ D) study: practical outcomes and implications for depression treatment in primary care. Primary care: Clinics in Office Practice, 34(3):505-519. https://doi.org/10.1016/j.pop.2007.05.006

Cha, Y., Erez, T., Reynolds, I. J., Kumar, D., Ross, J., Koytiger,G., … & Laifenfeld, D. (2018). Drug repurposing from the perspective of pharmaceutical companies.British Journal of Pharmacology,175(2), 168-180.https://doi.org/10.1111/bph.13798

Coppen, A., Shaw, D., Herzberg, B. &Maggs, R. (1967). Tryptophan in the treatment of depression. The Lancet, 290(7527), 1178-1180.https://doi.org/10.1016/S0140-6736(67)91894-6

Cowen, P. J., Parry-Billings, M. &Newsholme, E. A. (1989). Decreased plasma tryptophan levels in major depression. Journal of Affective Disorders, 16(1), 27-31.https://doi.org/10.1016/0165-0327(89)90051-7

Cuijpers, P., Reynolds III, C. F., Donker, T., Li, J., Andersson, G., & Beekman, A. (2012). Personalized treatment of adult depression: medication, psychotherapy, or both? A systematic review. Depression and Anxiety, 29(10), 855-864.https://doi.org/10.1002/da.21985

Czumaj, A., Zabielska, J., Pakiet, A., Mika, A., Rostkowska, O., Makarewicz, W., … &Stelmanska, E. (2019). In vivo effectiveness of orlistat in the suppression of human colorectal cancer cell proliferation. Anticancer Research, 39(7), 3815-3822.https://doi.org/10.21873/anticanres.13531

Delgado, P. L. (2000). Depression: the case for a monoamine deficiency. Journal of Clinical Psychiatry, 61(6), 7-11.

Dell’Osso, L., Carmassi, C., Mucci, F. &Marazziti, D. (2016). Depression, serotonin and tryptophan. Current Pharmaceutical Design, 22(8), 949-954.https://doi.org/10.2174/1381612822666151214104826

Dowrick, C. (2009). Beyond depression: a new approach to understanding and management. Oxford University Press, USA.

E Martin, A., A Schober, D., Nikolayev, A., V Tolstikov, V., H Anderson, W., E Higgs, R., … & M Witkin, J. (2017). Further evaluation of mechanisms associated with the antidepressantlike signature of scopolamine in mice. CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders), 16(4), 492-500.

Ebada, M. E. (2017). Drug repurposing may generate novel approaches to treating depression. Journal of Pharmacy and Pharmacology, 69(11), 1428-1436.https://doi.org/10.1111/jphp.12815

Fabbri, C., Kasper, S., Zohar, J., Souery, D., Montgomery, S., Albani, D., … &Serretti, A. (2021). Drug repositioning for treatment-resistant depression: hypotheses from a pharmacogenomic study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 104, 110050.https://doi.org/10.1016/j.pnpbp.2020.110050

Freitas, A. E., Neis, V. B., & Rodrigues, A. L. S. (2016). Agmatine, a potential novel therapeutic strategy for depression. European Neuropsychopharmacology, 26(12), 1885-1899.https://doi.org/10.1016/j.euroneuro.2016.10.013

Gahr, M. (2014). Agomelatine in the treatment of major depressive disorder: an assessment of benefits and risks. Current Neuropharmacology,12(5), 387-398.https://doi.org/10.2174/1570159X12999140619122914

Garnock-Jones, K. P., & Keating, G. M. (2009). Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Pediatric Drugs, 11, 203-226.https://doi.org/10.2165/00148581-200911030-00005

Goldberg, J. S., Bell Jr, C. E. & Pollard, D. A. (2014). Revisiting the monoamine hypothesis of depression: a new perspective. Perspectives in Medicinal Chemistry, 6, PMC-S11375.https://doi.org/10.4137/PMC.S11375

Goldstein, I., Burnett, A. L., Rosen, R. C., Park, P. W., &Stecher, V. J. (2019). The serendipitous story of sildenafil: an unexpected oral therapy for erectile dysfunction. Sexual Medicine Reviews, 7(1), 115-128.https://doi.org/10.1016/j.sxmr.2018.06.005
Gurpur, P. B., Liu, J., Burkin, D. J., & Kaufman, S. J. (2009). Valproic acid activates the PI3K/Akt/mTOR pathway in muscle and ameliorates pathology in a mouse model of Duchenne muscular dystrophy. The American Journal of Pathology, 174(3), 999-1008.

Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry, 23(1), 56.https://doi.org/10.1136/jnnp.23.1.56

Henriksen, K., Christiansen, C., & Karsdal, M. A. (2011). Serological biochemical markers of surrogate efficacy and safety as a novel approach to drug repositioning. Drug Discovery Today, 16(21-22), 967-975.https://doi.org/10.1016/j.drudis.2011.06.010

Herbert, J. (2013). Cortisol and depression: three questions for psychiatry. Psychological Medicine, 43(3), 449-469.https://doi.org/10.1017/S0033291712000955

Hillhouse, T. M. & Porter, J. H. (2015). A brief history of the development of antidepressant drugs: from monoamines to glutamate. Experimental and Clinical Psychopharmacology, 23(1), 1.https://doi.org/10.1037/a0038550

Holsboer, F. (2001). Stress, hypercortisolism and corticosteroid receptors in depression: implicatons for therapy.Journal of Affective Disorder, 62(1-2), 77-91.https://doi.org/10.1016/S0165-0327(00)00352-9

Hong, C. T., Chan, L., Hu, C. J., Lin, C. M., Hsu, C. Y., & Lin, M. C. (2017). Tamoxifen and the risk of Parkinson’s disease in female patients with breast cancer in asian people: a nationwide population-based study. Journal of Breast Cancer, 20(4), 356-360. https://doi.org/10.4048/jbc.2017.20.4.356

Howland, R. H. (2013).Mifepristone as a therapeutic agent in psychiatry. Journal of Psychological Nursing and Mental Health Services, 51(6), 11-14. https://doi.org/10.3928/02793695-20130513-01

Hughes, J. P., Rees, S., Kalindjian, S. B., & Philpott, K. L. (2011). Principles of early drug discovery. British Journal of Pharmacology, 162(6), 1239-1249.https://doi.org/10.1111/j.1476-5381.2010.01127.x

Hurlen, M., Abdelnoor, M., Smith, P., Erikssen, J., &Arnesen, H. (2002). Warfarin, aspirin, or both after myocardial infarction. New England Journal of Medicine, 347(13), 969-974.https://doi.org/10.1056/NEJMoa020496

Husain, M. I., Chaudhry, I. B., Khoso, A. B., Husain, M. O., Hodsoll, J., Ansari, M. A., … & Young, A. H. (2020). Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial. The Lancet Psychiatry, 7(6), 515-527.https://doi.org/10.1016/S2215-0366(20)30138-3

Institute of Health Metrics and Evaluation, 2023. Global Health Data Exchange (GHDx).

Keller, M., Montgomery, S., Ball, W., Morrison, M., Snavely,D., Liu, G., … &Reines, S. (2006). Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder.Biological Psychiatry, 59(3), 216-223.https://doi.org/10.1016/j.biopsych.2005.07.013

Kerr, J. L., Timpe, E. M., & Petkewicz, K. A. (2010). Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus. Annals of pharmacotherapy, 44(11), 1777-1785.https://doi.org/10.1345/aph.1P271
Khan, H., Bangar, A., Grewal, A. K., Bansal, P. & Singh, T. G. (2022). Caspase-mediated regulation of the distinct signaling pathways and mechanisms in neuronal survival. International Immunopharmacology, 110, 108951. https://doi.org/10.1016/j.intimp.2022.108951
Kinlein, S.A., Wilson, C.D.,& Karatsoreos, I.N. (2015). Dysregulated hypothalamic–pituitary–adrenal axis function contributes to altered endocrine and neurobehavioral responses to acute stress.Frontiers in psychiatry, 6, 31.https://doi.org/10.3389/fpsyt.2015.00031

Ko, Y. (2020). Computational drug repositioning: current progress and challenges. Applied Sciences, 10(15), 5076. https://doi.org/10.3390/app10155076

Kraus, C., Wasserman, D., Henter, I. D., Acevedo-Diaz, E., Kadriu, B., & Zarate Jr, C. A. (2019). The influence of ketamine on drug discovery in depression. Drug Discovery Today, 24(10), 2033-2043.https://doi.org/10.1016/j.drudis.2019.07.007

Kupfer, D.J. (2005).The increasing medical burden in bipolar disorder. Jama, 293(20), 2528-2530.10.1001/jama.293.20.2528

Law, G. L., Tisoncik-Go, J., Korth, M. J. &Katze, M. G. (2013). Drug repurposing: a better approach for infectious disease drug discovery?. Current Opinion in Immunology, 25(5), 588-592.https://doi.org/10.1016/j.coi.2013.08.004

Li, J., Yang, R., Xia, K., Wang, T., Nie, B., Gao, K., … & Wang, W. (2018). Effects of stress on behavior and resting-state fMRI in rats and evaluation of Telmisartan therapy in a stress-induced depression model. BMC Psychiatry, 18(1), 1-13.https://doi.org/10.1186/s12888-018-1880-y

Little A. (2009). Treatment-resistant depression. American family physician, 80(2),167-172.

Mann, J. J. (2005). The medical management of depression. New England Journal of Medicine, 353(17), 1819-1834.https://doi.org/10.1056/NEJMra050730

Martinowich, K., Manji, H. & Lu, B. (2007). New insights into BDNF function in depression and anxiety. Nature Neuroscience, 10(9), 1089-1093.https://doi.org/10.1038/nn1971

McGirr, A., Vöhringer, P. A., Ghaemi, S. N., Lam, R. W., & Yatham, L. N. (2016). Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. The Lancet Psychiatry, 3(12), 1138-1146.https://doi.org/10.1016/S2215-0366(16)30264-4

Meyer, J. H., Ginovart, N., Boovariwala, A., Sagrati, S., Hussey, D., Garcia, A., …& Houle, S. (2006). Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Archives of General Psychiatry, 63(11), 1209-1216.https://doi.org/10.1001/archpsyc.63.11.1209

Motaghinejad, M., Farokhi, N., Motevalian, M., & Safari, S. (2020). Molecular, histological and behavioral evidences for neuroprotective effects of minocycline against nicotine-induced neurodegeneration and cognition impairment: Possible role of CREB-BDNF signaling pathway. Behavioural Brain Research, 386, 112597. https://doi.org/10.2174/1871527316666170309142646

Moussaieff, A., Gross, M., Nesher, E., Tikhonov, T., Yadid, G., & Pinhasov, A. (2012). Incensole acetate reduces depressive-like behavior and modulates hippocampal BDNF and CRF expression of submissive animals. Journal of psychopharmacology, 26(12), 1584-1593.https://doi.org/10.1177/0269881112458729

Neumeister, A. (2003). Tryptophan depletion, serotonin, and depression: where do we stand?. Psychopharmacology bulletin, 37(4), 99-115.

Nosengo, N. (2016). New tricks for old drugs. Nature, 534(7607), 314-316.https://doi.org/10.1038/534314a

Nygaard, H. B., van Dyck, C. H., & Strittmatter, S. M. (2014). Fyn kinase inhibition as a novel therapy for Alzheimer’s disease. Alzheimer’s research & therapy, 6, 1-8.https://doi.org/10.1186/alzrt238

Osterloh, I. H. (2004). The discovery and development of Viagra®(sildenafil citrate). In Sildenafil (pp. 1-13). Basel: Birkhäuser Basel.https://doi.org/10.1007/978-3-0348-7945-3_1

Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., … &Schatzberg, A. F. (2016). Major depressive disorder. Nature Reviews Disease Primers, 2(1), 1-20. https://doi.org/10.1038/nrdp.2016.65

Palomares, T., Cordero, M., Bruzos-Cidon, C., Torrecilla, M., Ugedo, L., & Alonso-Varona, A. (2018). The neuroprotective effect of conditioned medium from human adipose-derived mesenchymal stem cells is impaired by N-acetyl cysteine supplementation. Molecular Neurobiology, 55, 13-25.https://doi.org/10.1007/s12035-017-0714-0

Palumbo, A., Facon, T., Sonneveld, P., Blade, J., Offidani, M., Gay, F.,… &Harousseau, J. L. (2008). Thalidomide for treatment of multiple myeloma: 10 years later. Blood, The Journal of the American Society of Hematology,111(8), 3968-3977.https://doi.org/10.1182/blood-2007-10-117457

Pariante, C. M. (2017). Why are depressed patients inflamed? A reflection on 20 years of research on depression, glucocorticoid resistance and inflammation. European Neuropsychopharmacology, 27(6), 554-559. https://doi.org/10.1016/j.euroneuro.2017.04.001

Plotsky, P. M., Owens, M. J., &Nemeroff, C. B. (1998). Psychoneuroendocrinology of depression: hypothalamic-pituitary-adrenal axis. Psychiatric Clinics of North America, 21(2), 293-307.https://doi.org/10.1016/s0193-953x(05)70006-x

Potter, D. E., & Choudhury, M. (2014). Ketamine: repurposing and redefining a multifaceted drug. Drug Discovery Today, 19(12), 1848-1854.https://doi.org/10.1016/j.drudis.2014.08.017

Prabhakar, N. K., Khan, H., Grewal, A. K. & Singh, T.G. (2022). Intervention of neuroinflammation in the traumatic brain injury trajectory: In vivo and clinical approaches. International Immunopharmacology, 108, 108902.https://doi.org/10.1016/j.intimp.2022.108902

Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., … & Pirmohamed, M. (2019).Drug repurposing: progress, challenges and recommendations. Nature Reviews Drug Discovery,18(1), 41-58.https://doi.org/10.1038/nrd.2018.168

Pytka, K., Młyniec, K., Podkowa, K., Podkowa, A., Jakubczyk, M., Żmudzka, E., … &Filipek, B. (2017). The role of melatonin, neurokinin, neurotrophic tyrosine kinase and glucocorticoid receptors in antidepressant-like effect. Pharmacological Reports, 69(3), 546-554. https://doi.org/10.1016/j.pharep.2017.01.026
Randolph, M., &Tosti, A. (2021). Oral minoxidil treatment for hair loss: A review of efficacy and safety. Journal of the American Academy of Dermatology, 84(3), 737-746.https://doi.org/10.1016/j.jaad.2020.06.1009

Rascol, O., Fabbri, M., &Poewe, W. (2021). Amantadine in the treatment of Parkinson’s disease and other movement disorders. The Lancet Neurology, 20(12), 1048-1056.https://doi.org/10.1016/S1474-4422(21)00249-0

Rihal, V., Kaur, A., Singh, T. G. & Abdel-Daim, M. M. (2022). Therapeutic and mechanistic intervention of vitamin D in neuropsychiatric disorders. Psychiatry Research, 114782.https://doi.org/10.1016/j.psychres.2022.114782

Rodriguez, J.M., Monsalves-Alvarez,M., Henriquez, S., Llanos, M.N.,&Troncoso, R. (2016). Glucocorticoid resistance in chronic diseases. Steroids, 115,182-192. https://doi.org/10.1016/j.steroids.2016.09.010

Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., … & Fisher, P. B. (2005). β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature, 433(7021), 73-77.https://doi.org/10.1038/nature03180

Schildkraut, J.J. (1965).The catecholamine hypothesis of affective disorders: a review of supporting evidence.American Journal of Psychiatry, 122(5), 509-522.https://doi.org/10.1176/ajp.122.5.509
Souery, D., Papakostas, G. I., & Trivedi, M. H. (2006). Treatment-resistant depression. Journal of Clinical Psychiatry, 67, 16.

Taylor, C., Fricker, A.D., Devi, L.A.,& Gomes, I. (2005). Mechanisms of action of antidepressants: from neurotransmitter systems to signaling pathways.Cellular Signaling, 17(5), 549-557.https://doi.org/10.1016/j.cellsig.2004.12.007

Teo, S. K., Resztak, K. E., Scheffler, M. A., Kook, K. A., Zeldis, J. B., Stirling, D. I., & Thomas, S. D. (2002). Thalidomide in the treatment of leprosy. Microbes and Infection, 4(11), 1193-1202.https://doi.org/10.1016/s1286-4579(02)01645-3

Tripathy, S., Dassarma, B., Roy, S., Chabalala, H.,&Matsabisa, M. G. (2020). A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic. International Journal of Antimicrobial Agents, 56(2), 106028.https://doi.org/10.1016/j.ijantimicag.2020.106028

Tsao, C. W., Lin, Y. S., Chen, C. C., Bai, C. H. & Wu, S. R. (2006). Cytokines and serotonin transporter in patients with major depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 30(5), 899-905.https://doi.org/10.1016/j.pnpbp.2006.01.029

Weilburg, J. B. (2004). An overview of SSRI and SNRI therapies for depression. Managed Care (Langhorne, Pa.), 13(6 Suppl Depression), 25-33.

Wilkes, S. (2008). The use of bupropion SR in cigarette smoking cessation. International Journal of Chronic Obstructive Pulmonary Disease, 3(1), 45-53. https://doi.org/10.2147/copd.s1121

Yang, T., Nie, Z., Shu, H., Kuang, Y., Chen, X., Cheng, J., … & Liu, H. (2020). The role of BDNF on neural plasticity in depression. Frontiers in Cellular Neuroscience, 14, 82.https://doi.org/10.3389/fncel.2020.00082

You, H., Lu, W., Zhao, S., Hu, Z., & Zhang, J. (2013). The relationship between statins and depression: a review of the literature. Expert Opinion on Pharmacotherapy, 14(11), 1467-1476.https://doi.org/10.1517/14656566.2013.803067

Zhang, Q. Q., Li, W. S., Liu, Z., Zhang, H. L., Ba, Y. G., & Zhang, R. X. (2020). Metformin therapy and cognitive dysfunction in patients with type 2 diabetes: a meta-analysis and systematic review. Medicine, 99(10).https://doi.org/10.1097/MD.0000000000019378

Zhao, K., & So, H. C. (2018). Drug repositioning for schizophrenia and depression/anxiety disorders: a machine learning approach leveraging expression data. IEEE journal of Biomedical and Health Informatics, 23(3), 1304-1315.https://doi.org/10.1109/JBHI.2018.2856535

Zheng, W., Sun, W. &Simeonov, A. (2018). Drug repurposing screens and synergistic drug‐combinations for infectious diseases. British Journal of Pharmacology, 175(2), 181-191.https://doi.org/10.1111/bph.13895

How to Cite

Mimansa Kandhwal, Amarjot Kaur Grewal, Varinder Singh, Heena Khan and Thakur Gurjeet Singh . Drug Repurposing Approaches for Depression: Rationale and its Clinical Experience. J. Pharm. Technol. Res. Manag.. 2023, 11, 27-38
Drug Repurposing Approaches for Depression: Rationale and its Clinical Experience

Current Issue

ISSN Print2321-2217
ISSN Online2321-2225
RNI No.CHAENG/2013/50088
OA Policy

Publisher's policy of the journal at Sherpa UK for the submitted, accepted, and published articles. Click OAPolicy

Plan-S Compliance

To check compliance, one has to use the Journal Check Tool (JCT). This tool provided by cOAlition S (European funders) for the researchers (fundee) to check the compliance with the journal.

Recommend journal to your library

You can recommend the journal being a researcher or faculty member to your library. We will post a copy of the Journal to your library on your behalf at free of cost.
Click here: Recommend Journal

Preprint Arxiv Submission

The authors are encouraged to submit the author’s copy (preprint) to appropriate preprint archives e.g. https://arxiv.org and/or on https://indiarxiv.org or institutional repositories (e.g., D Space) before paper acceptance by the editor of Journal. After publications of the paper author(s) should mention the citation information, title and abstract along with DOI number of the publication carefully on the required page of the depository(ies).

Contact: Phone: +91-172-2741000, +91-172-4691800

Email : editor.jptrm@chitkara.edu.in;

Abstract and Indexing


This work is licensed under a Creative Commons Attribution 4.0 International License.

Articles in Journal of Pharmaceutical Technology, Research and Management (J. Pharm. Tech. Res. Management) by Chitkara University Publications are Open Access articles that are published with licensed under a Creative Commons Attribution- CC-BY 4.0 International License. Based on a work at https://jptrm.chitkara.edu.in/. This license permits one to use, remix, tweak and reproduction in any medium, even commercially provided one give credit for the original creation.

View Legal Code of the above-mentioned license, https://creativecommons.org/licenses/by/4.0/legalcode

View Licence Deed here https://creativecommons.org/licenses/by/4.0/

Creative Commons License

Journal of Pharmaceutical Technology, Research and Management by Chitkara University Publications is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at https://jptrm.chitkara.edu.in//